IDBiologics, Inc.
IDBiologics is a private biotechnology company founded in 2017, focused on discovering and developing human monoclonal antibodies (mAbs) for the prevention and treatment of infectious diseases. Originating from Vanderbilt University Medical Center, it leverages innovative fully human mAb platforms to rapidly discover broad and potent therapeutic antibodies. The company has a diverse pipeline including clinical candidates for infectious diseases such as BK virus, influenza, Zika, and others, with a mission to develop solutions for global health threats and pandemics.
Industries
Nr. of Employees
small (1-50)
IDBiologics, Inc.
Products
Monoclonal antibody candidate for BK virus
Human monoclonal antibody program with lead and backup clinical candidates developed to prevent or treat BK virus reactivation and associated nephropathy in immunocompromised patients.
Pan-influenza A and B monoclonal antibody combination
Development of two ultra-potent human antibodies (one against influenza A and one against influenza B) engineered for extended duration (~6 months) intended for seasonal off-the-shelf prophylaxis.
Cross-neutralizing RSV / HMPV monoclonal antibody candidate
A single human monoclonal antibody shown in preclinical models to cross-neutralize respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).
Zika prophylactic monoclonal antibody candidate
An ultra-potent neutralizing human monoclonal antibody being developed as an off-the-shelf pre-exposure prophylaxis against Zika virus infection.
Rift Valley fever virus (RVFV) two-antibody therapeutic
A two-antibody medicine derived from human antibodies that inhibit RVFV replication and are being developed for treatment and prevention, with extended half-life engineering and non-overlapping epitope binding.
Enterovirus D68 monoclonal antibody program
Antibody discovery program targeting Enterovirus D68 to provide therapeutic options where no vaccines or treatments currently exist.
Monoclonal antibody candidate for BK virus
Human monoclonal antibody program with lead and backup clinical candidates developed to prevent or treat BK virus reactivation and associated nephropathy in immunocompromised patients.
Pan-influenza A and B monoclonal antibody combination
Development of two ultra-potent human antibodies (one against influenza A and one against influenza B) engineered for extended duration (~6 months) intended for seasonal off-the-shelf prophylaxis.
Cross-neutralizing RSV / HMPV monoclonal antibody candidate
A single human monoclonal antibody shown in preclinical models to cross-neutralize respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).
Zika prophylactic monoclonal antibody candidate
An ultra-potent neutralizing human monoclonal antibody being developed as an off-the-shelf pre-exposure prophylaxis against Zika virus infection.
Rift Valley fever virus (RVFV) two-antibody therapeutic
A two-antibody medicine derived from human antibodies that inhibit RVFV replication and are being developed for treatment and prevention, with extended half-life engineering and non-overlapping epitope binding.
Enterovirus D68 monoclonal antibody program
Antibody discovery program targeting Enterovirus D68 to provide therapeutic options where no vaccines or treatments currently exist.
Services
End-to-end antibody development to Phase 1
Contract development services covering antibody discovery, preclinical assessment (in vitro and in vivo), preclinical safety/toxicology, manufacturing process development, production of clinical material, and Phase 1 clinical trial execution.
End-to-end antibody development to Phase 1
Contract development services covering antibody discovery, preclinical assessment (in vitro and in vivo), preclinical safety/toxicology, manufacturing process development, production of clinical material, and Phase 1 clinical trial execution.
Expertise Areas
- Therapeutic monoclonal antibody discovery and development
- Antibody engineering and half-life extension
- Preclinical in vitro and in vivo antiviral testing
- CMC and clinical-supply manufacturing process development
Key Technologies
- Fully human monoclonal antibody discovery platform
- Antibody sequence engineering and optimization
- In vitro antiviral neutralization assays
- In vivo animal efficacy models (preclinical)